Long-term study of ACP-204 for psychosis in Lewy body dementia
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests a medication called ACP-204 for psychosis (hallucinations or delusions) in people with Lewy body dementia. It is a long-term extension open to patients who completed a previous ACP-204 study, to see if the drug continues to be helpful and safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have finished the earlier ACP-204-012 study and did not leave it early
- You can come to all study visits with a caregiver or family member
- You understand the study and can give permission (or have a legal representative give permission, with your agreement)
- If you are a woman, you cannot become pregnant; if you are a man, you agree to use birth control or avoid pregnancy risks for 3 months after the last dose
- You are not in hospice, bedridden, or receiving end-of-life care
- You do not have certain medical conditions or take medications that would make the study unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ACP-204 for people with dementia from Lewy body disease or Parkinson's who also have hallucinations or delusions. The goal is to see if the drug can safely reduce these symptoms without worsening thinking problems.
This study tests a long-term medicine (ACP-204) for people with Alzheimer's disease who also have psychosis (hallucinations or delusions). If you took part in the earlier ACP-204 study, this open-label extension lets you continue receiving the medicine to see how well it works over time.
This trial tests a long-term treatment (ML-007C-MA) for people with Alzheimer's disease who have psychosis. It is for those who already completed an earlier study with the same drug and may benefit from continuing it. The goal is to see if ongoing treatment is helpful and safe.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
This study looks at how brain changes affect attention and thinking in people with Lewy body dementia. It includes brain scans, an EEG, and a medication option to see if it helps with symptoms.
Hear when a new Lewy Body Dementia Psychosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.